Literature DB >> 20477283

Mathematical models of the epidemiology and control of drug-resistant TB.

Ted Cohen1, Christopher Dye, Caroline Colijn, Brian Williams, Megan Murray.   

Abstract

Recent reports of extensively drug-resistant TB in South Africa have renewed concerns that antibiotic resistance may undermine progress in TB control. We review three major questions for which mathematical models elucidate the epidemiology and control of drug-resistant TB. How is multiple drug-resistant Mycobacterium tuberculosis selected for in individuals exposed to combination chemotherapy? What factors determine the prevalence of drug-resistant TB? Which interventions to prevent the spread of drug-resistant TB are effective and feasible? Models offer insight into the acquisition and amplification of drug resistance, reveal the importance of distinguishing the intrinsic and extrinsic determinants of the reproductive capacity of drug-resistant M. tuberculosis, and demonstrate the cost effectiveness of interventions for drug-resistant TB. These models also highlight knowledge gaps for which new research will improve our ability to project trends of drug resistance and develop more effective policies for its control.

Entities:  

Year:  2009        PMID: 20477283     DOI: 10.1586/17476348.3.1.67

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  17 in total

1.  The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.

Authors:  Gwenan M Knight; Caroline Colijn; Sourya Shrestha; Mariam Fofana; Frank Cobelens; Richard G White; David W Dowdy; Ted Cohen
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

Review 2.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

Review 3.  Epidemiological models of Mycobacterium tuberculosis complex infections.

Authors:  Cagri Ozcaglar; Amina Shabbeer; Scott L Vandenberg; Bülent Yener; Kristin P Bennett
Journal:  Math Biosci       Date:  2012-03-01       Impact factor: 2.144

4.  Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis.

Authors:  Florian M Marx; Ted Cohen; Nicolas A Menzies; Joshua A Salomon; Grant Theron; Reza Yaesoubi
Journal:  Lancet Glob Health       Date:  2020-09       Impact factor: 26.763

5.  On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data.

Authors:  Ted Cohen; Helen E Jenkins; Chunling Lu; Megan McLaughlin; Katherine Floyd; Matteo Zignol
Journal:  Drug Resist Updat       Date:  2014-10-06       Impact factor: 18.500

6.  Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study.

Authors:  Eline L Korenromp; Philippe Glaziou; Christopher Fitzpatrick; Katherine Floyd; Mehran Hosseini; Mario Raviglione; Rifat Atun; Brian Williams
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

7.  Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling.

Authors:  D W Dowdy; R Houben; T Cohen; M Pai; F Cobelens; A Vassall; N A Menzies; G B Gomez; I Langley; S B Squire; R White
Journal:  Int J Tuberc Lung Dis       Date:  2014-09       Impact factor: 2.373

8.  Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis.

Authors:  Sourya Shrestha; Gwenan M Knight; Mariam Fofana; Ted Cohen; Richard G White; Frank Cobelens; David W Dowdy
Journal:  Open Forum Infect Dis       Date:  2014-08-30       Impact factor: 3.835

Review 9.  The past and future of tuberculosis research.

Authors:  Iñaki Comas; Sebastien Gagneux
Journal:  PLoS Pathog       Date:  2009-10-26       Impact factor: 6.823

Review 10.  Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies.

Authors:  Alice Zwerling; Sourya Shrestha; David W Dowdy
Journal:  Adv Med       Date:  2015-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.